Tirzepatide and Type 2 Diabetes: HbA1c Reduction Research Data

The SURPASS Clinical Program: Overview

The SURPASS trials evaluated tirzepatide specifically in populations with type 2 diabetes, covering monotherapy, combination with oral agents, and combination with injectable therapies. These five pivotal trials established tirzepatide's position as the most efficacious HbA1c-reducing agent in the incretin class.

SURPASS-1: Tirzepatide Monotherapy

Design: Tirzepatide (5, 10, or 15 mg) vs. placebo in T2D inadequately controlled on diet/exercise alone (N=478, 40 weeks)

Baseline HbA1c: ~7.9%

HbA1c reduction from baseline:

• Tirzepatide 5 mg: −1.87%
• Tirzepatide 10 mg: −1.89%
• Tirzepatide 15 mg: −2.07%
• Placebo: −0.04%

HbA1c <7.0% (ADA target):

• 5 mg: 87%
• 10 mg: 89%
• 15 mg: 92%
• Placebo: 20%

HbA1c <5.7% (normoglycemia):

• 15 mg: 34% of participants

SURPASS-2: Tirzepatide vs. Semaglutide 1 mg

Design: Tirzepatide (5, 10, 15 mg) vs. semaglutide 1 mg in T2D on metformin (N=1879, 40 weeks)

HbA1c reduction:

• Tirzepatide 5 mg: −2.01%
• Tirzepatide 10 mg: −2.24%
• Tirzepatide 15 mg: −2.30%
• Semaglutide 1 mg: −1.86%

All tirzepatide doses achieved statistically superior HbA1c reduction vs. semaglutide 1 mg. The 15 mg tirzepatide arm achieved a 0.44% greater HbA1c reduction than semaglutide 1 mg.

Normoglycemia (HbA1c <5.7%) rates:

• Tirzepatide 15 mg: 27%
• Semaglutide 1 mg: 9%

SURPASS-3: Tirzepatide vs. Insulin Degludec

Design: Tirzepatide (5, 10, 15 mg) vs. insulin degludec (titrated) in T2D on metformin ± SGLT2i (N=1444, 52 weeks)

HbA1c reduction:

• Tirzepatide 10 mg: −2.37% vs. insulin degludec −1.34%
• Tirzepatide 15 mg: −2.59% vs. insulin degludec −1.34%

Weight: Tirzepatide 15 mg: −13.9 kg; insulin degludec: +3.0 kg (16.9 kg separation)

Hypoglycemia: Tirzepatide had significantly fewer hypoglycemic events despite superior glycemic control — consistent with the glucose-dependent mechanism.

SURPASS-4: Tirzepatide vs. Insulin Glargine in High CV Risk

Design: Tirzepatide (5, 10, 15 mg) vs. insulin glargine in T2D with high CV risk on 1–3 oral agents (N=2002, 52 weeks)

HbA1c reduction:

• Tirzepatide 15 mg: −2.58%
• Insulin glargine: −1.44%

Normoglycemia: Tirzepatide 15 mg achieved HbA1c <5.7% in 37% vs. 3% with insulin glargine.

SURPASS-5: Tirzepatide Added to Insulin Glargine

Design: Tirzepatide (5, 10, 15 mg) vs. placebo added to insulin glargine ± metformin (N=475, 40 weeks)

HbA1c reduction:

• Tirzepatide 5 mg: −2.11%
• Tirzepatide 10 mg: −2.40%
• Tirzepatide 15 mg: −2.34%
• Placebo: −0.86%

Despite being added to basal insulin, tirzepatide produced 1.5–1.6% additional HbA1c reduction, with simultaneous weight loss (6–8 kg) allowing insulin dose reduction.

Cross-Agent HbA1c Comparison

Comparing maximum approved doses across incretin therapies (indirect comparison, different trial designs):

Agent	Mechanism	Max dose	Max HbA1c reduction
Tirzepatide	GLP-1R + GIPR	15 mg QW	~2.3–2.6%
Semaglutide	GLP-1R	2 mg QW	~1.8–2.0%
Dulaglutide	GLP-1R	4.5 mg QW	~1.7%
Liraglutide	GLP-1R	1.8 mg QD	~1.5%
Exenatide	GLP-1R	10 mcg BID	~1.1%
Sitagliptin (DPP-4i)	GLP-1/GIP indirect	100 mg QD	~0.7%

Tirzepatide achieves approximately 25–40% greater HbA1c reduction than best-in-class GLP-1 monotherapy, consistent with the additive/synergistic GIP receptor contribution to beta cell stimulation.

Beta Cell Preservation: Preclinical Data

Beyond glycemic lowering, tirzepatide's combined incretin receptor activation may modify the underlying disease progression in T2D by preserving beta cell mass and function.

Key Preclinical Findings

Rodent models (db/db mice, ZDF rats):

• Tirzepatide treatment: 40–60% greater beta cell area vs. vehicle control
• Reduced beta cell apoptosis markers (cleaved caspase-3, TUNEL staining)
• Increased beta cell proliferation (Ki67+ cells)
• Improved insulin secretory capacity (glucose-stimulated insulin secretion in isolated islets)

Mechanism of beta cell preservation:

1. GLP-1R activation: PDX-1 upregulation, Nkx6.1 stabilization (transcription factors for beta cell identity)
2. GIPR activation: PI3K/Akt survival signaling in beta cells
3. Reduced glucotoxicity and lipotoxicity (secondary to improved glucose/lipid homeostasis)
4. Decreased ER stress markers (GRP78, CHOP) in islets

SURPASS-2 C-peptide data (clinical): Fasting C-peptide increased significantly with tirzepatide vs. semaglutide at 40 weeks, suggesting superior preservation or enhancement of endogenous insulin secretory capacity.

Research Summary

The SURPASS program establishes tirzepatide as the current benchmark for HbA1c reduction in T2D pharmacotherapy. For researchers studying beta cell biology, the combination of GLP-1R and GIPR activation provides a powerful tool to investigate dual incretin signaling in islet protection, glucose-stimulated insulin secretion, and T2D pathophysiology.

Research-grade tirzepatide available through peptidescientists.com for diabetes and beta cell biology research.